Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer.

Autor:	Al-Samsam S; Department of Oncology, Regional Hospital Liberec, Czech Republic., Bartos J; Department of Oncology, Regional Hospital Liberec, Czech Republic., Samal V; Department of Urology, Regional Hospital Liberec, Czech Republic., Dvorak J; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic., Kolarova H; MATSTAT, Prague, Czech Republic., Richter I; Department of Oncology, Regional Hospital Liberec, Czech Republic.; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.; Technical University of Liberec, Czech Republic.
Jazyk:	angličtina
Zdroj:	Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2024 Mar 18; Vol. 29 (1), pp. 1-9. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).
DOI:	10.5603/rpor.99028
Abstrakt:	Background: The aim was to assess therapeutic outcomes and tolerance in patients with metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor targeted agents (ARTA) treatment at one oncological center in the Czech Republic. Materials and Methods: Retrospective analysis of 64 patients with mCRPC treated with abiraterone (50 patients) and enzalutamide (14 patients) in the first line of this disease was conducted. Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. Results: The median follow-up was 28.4 months. The median PFS was 15.4 months [95% confidence interval (CI): 12.3-18.5], median OS was 38.2 months (95% CI: 19.9-56.5). Regression analysis demonstrated a favorable prognostic effect on PFS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of prostate-specific antigen (PSA) ≥ 50% within 3 months, in patients younger than 74 years and in overall performance status (PS) 0. Regression analysis demonstrated a favorable prognostic effect on OS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of PSA ≥ 50 % within 3 months and in patients with overall PS 0. Adverse effects grade 3-4 were reported in 17 (27.9%) patients in abirateron arm and in 1 (7.1%) patient in enzalutamide arm. Conclusion: The analysis of patients with mCRPC treated with ARTA in the first line showed that ARTA represents an effective and safe therapy and contributes to longer survival. Competing Interests: Conflict of interest: The authors state that there are no conflicts of interest regarding the publication of this article. (© 2024 Greater Poland Cancer Centre.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu